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AG36 is the biotransformation product of triterpenoid saponin from Ardisia gigantifolia
stapf. In this study, the antitumor activity and underlying molecular mechanisms of
AG36 against human breast MCF-7, MDA-MB-231, and SK-BR-3 cancer cells were
investigated. AG36 inhibited the viability of MCF-7, MDA-MB-231, and SK-BR-3 cells
in a dose and time-dependent manner, with an IC50 of approximately 0.73, 18.1, and
23.4 µM at 48 h, respectively. AG36 obviously induced apoptosis and G2/M arrest
of all the three breast cancer cells. Moreover, AG36 decreased the protein expression
of cycle regulatory proteins cyclin B1 or cyclin D1. In MCF-7 and MDA-MB-231 cells,
AG36 strongly increased the cleaved caspase-3 and -8 protein expressions, while in
SK-BR-3 cells, AG36 only increased the protein expression of cleaved caspase-3. In
all the three breast cancer cells, the ratio of Bax/Bcl-2 and cytosolic cytochrome c
content increased significantly compared with control group. The death receptor-related
proteins Fas/FasL, TNFR1, and DR5 were detected by Western blot, it showed that
different breast cancer cells activated the death receptor-mediated extrinsic caspase-8
pathway through different receptors. In addition, the caspase-8 inhibitor z-IETD-fmk
could significantly block AG36-triggered MCF-7 cells apoptosis. The in vivo studies
showed that AG36 significantly inhibited the growth of MCF-7 xenograft tumors in
BALB/c nude mice comparing with control. In conclusion, AG36 inhibited MCF-7, MDA-
MB-231, and SK-BR-3 cells proliferation by the intrinsic mitochondrial and the extrinsic
death receptor pathways and AG36 might be a potential breast cancer therapeutic
agent.
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INTRODUCTION
The rhizome of Ardisia gigantifolia stapf. is a traditional Chinese medicine used as an
expectorant for the treatment of traumatic injury, rheumatism, muscles, and bones pain.
It is an evergreen dwarf shrub mostly distributed in the provinces of Guangxi, Jiangxi,
and Fujian in China (Jiangsu New Medicinal College, 2001). According to previous studies,
triterpenoid saponins from A. gigantifolia stapf. have shown antitumour activities (Li et al.,
2009; Yokosuka et al., 2009; Gong et al., 2010; Mu et al., 2010, 2012). Among them,
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cyclamiretin A 3β-O-{α-L-rhamnopyranosyl-(1→3)-[β-D-
xylopyranosyl-(1→2)]-β-D-glucopyranosyl-(1→4)-[β-D-gluco-
pyranosyl-(1→2)]-α-L-arabinopyranoside} (AG4) had prom-
inent cytotoxicity against MCF-7 cells (Zheng et al., 2013). In
order to discover new anticancer lead compounds, AG4 was
biotransformated by Alternaria alternata AS 3.6872 to obtain
AG36 (Mu et al., 2015). The structure of AG36 is similar with
that of AG4, but with four-sugar units at C-3 (Figure 1), and
AG36 showed better cytotoxicity than AG4 against human breast
cancer MCF-7 cells.
Breast cancer is one of the most common cancers for women
worldwide (Guo et al., 2011). Globally, from 1980 to 2010,
the incidence increased with an annual growth rate of 3.1%,
breast cancer related mortality is still at a high level recently
(Forouzanfar et al., 2011). The limitations associated with new
therapeutic approaches for breast cancer, such as metastasis and
relapse make breast cancer still a challenge (Baselga et al., 2012).
In this study, we reported the anti-proliferative activity of AG36
against breast cancer cells in vitro and in vivo and unveiled the
potential antitumor mechanisms of AG36. Our work provides
experimental evidence for the medicinal applications of AG36
which may serve as a potential drug against human breast cancer.
MATERIALS AND METHODS
Chemicals and Reagents
AG36 (purity: >99%) was the biotransformation product of
triterpenoid saponin AG4 from A. gigantifolia stapf. as previously
described (Mu et al., 2015). The Dulbecco’s phosphate buffered
saline (DPBS), protease inhibitor cocktail, gelatin, and 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
were purchased from Sigma-Aldrich (St. Louis, MO, USA).
The primary antibodies for cleaved-caspase-3, cleaved-caspase-8,
deaved-caspase-9, Bax, Bcl-2, cytochrome c, TNFR1, Fas, FasL,
DR5, and β-actin as well as all of the secondary antibodies were
purchased from Cell Signaling Technology (Danvers, MA, USA).
Cell Culture
The MCF-7 cell line was a kind gift of Prof. Ming Gang Bi from
Institute of Medicinal Plant Development, Chinese Academy of
Medical Sciences and Peking Union Medical College. The MDA-
MB-231 and SK-BR-3 cell lines were purchased from Cell Culture
Collection of Chinese Academy of Medical Sciences (Beijing,
China). MCF-7 and SK-BR-3 cells were grown in Dulbecco’s
FIGURE 1 | Structure of AG36.
modified Eagle’s medium (DMEM, Gibco) supplemented with
10% fetal bovine serum (FBS) and 1% penicillin/streptomycin in
a humidified atmosphere containing 5% CO2 at 37◦C. MDA-MB-
231 cells were grown in L-15 medium containing 10% FBS at
37◦C in non-CO2 conditions.
Cell Viability Assay
The cell viability was evaluated by MTT assay. Briefly, MCF-7
cells were seeded at 2 × 104 cells/well into 96-well plates and
cultured in DMEM medium at 37◦C for 24 h. The cells were
then treated with final concentrations of AG36 (0, 0.2, 0.5, 1.0,
and 1.5 µM) for 24, 48, and 72 h, respectively. MTT solution
was added to each well and incubated for 4 h. The supernatant
was aspired, and DMSO was used to dissolve the formazan
crystals, and cellular viability was determined by measuring the
absorbance at 570 nm by an enzyme-linked immunosorbent
assay (ELISA) plate reader (Perkin-Elmer, Inc., 1420-012, China).
Analysis of Cell Cycle by PI Staining
MCF-7 cells (1× 105/well) were seeded in six-well plates, treated
by AG36 at various concentrations (0, 0.5, 1.0, and 1.5 µM) for
48 h, washed with PBS, and fixed with 70% (v/v) ethanol at 4◦C
for 1 h. The cells were washed with PBS twice and stained by
50 µg/mL PI and 10 µg/mL RNase A for 30 min in the dark (Fang
et al., 2012). The cell cycle was measured using FACS Calibur flow
cytometer (BD Biosciences, USA).
Measurement of Cell Apoptosis
Apoptosis of cells was conducted using double staining with
Annexin V-FITC and PI. After treatment by AG36 for 48 h,
MCF-7 cells (AG36: 0, 0.5, 1.0, and 1.5 µM), MDA-MB-231
and SK-BR-3 cells (AG36: 0, 10, 15, and 20 µM) were collected
and stained by Annexin V-FITC kit (Becton Dickinson, San
Jose, CA, USA) Briefly, cells were washed twice with cold PBS
and re-suspended in 300 µl binding buffer containing 10 µl
Annexin V-FITC stock and 10 µL PI. The cells were incubated
for 15 min at room temperature in dark and then analyzed using
flow cytometry (FACS Calibur; Becton Dickinson, San Jose, CA,
USA). In some experiments, caspase-8 inhibitor Z-IETD-FMK
with final concentration of 10 µM was added into fresh medium
of MCF-7 cells 1 h before AG36 was added. In some experiments,
caspase-8 inhibitor Z-IETD-FMK with final concentration of
10 µM was added into fresh medium of MCF-7 cells 1 h before
AG36 was added.
Western Blot Analysis
For the Western blot analysis, after culture with AG36 for 48 h,
MCF-7 cells (0, 0.5, 1.0, and 1.5 µM), MDA-MB-231 and SK-
BR-3 cells (AG36: 0, 10, 15, and 20 µM) cells were collected by
trypsinization and washed with cold PBS. The collected cells were
lysed in total protein extraction reagent and proteinase inhibitors.
The cell lysates were centrifuged at 12,000× g for 15 min at 4◦C.
The protein concentration of the supernatants was determined by
the BCA protein assay kit. Equal amounts of protein from each
sample were separated on SDS-PAGE and transferred to a PVDF
membrane. Membranes were blocked in 5% nonfat dry milk in
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TBST at room temperature for 1 h. Subsequently, the membranes
were then washed three times and probed with different primary
antibodies targeting cyclin B1, cyclin D1, cytochrome c, Bax, Bcl-
2, caspase-3 caspase-8, caspase-9, FasL, Fas, DR5, and TNFR1 at
4◦C overnight. The immunoblots were washed three times with
TBST buffer and incubated with the HRP-conjugated secondary
antibodies for 1 h at room temperature. The load protein was
normalized to β-actin and the protein bands were enhanced
with the enhanced chemiluminescence reagent (Pierce, Rockford,
IL, USA).
In vivo Xenograft Studies
Female BALB/c nude mice (5 weeks old, 18–19 g) were supplied
by Beijing Vital River Laboratory Animal Co. Ltd. (Beijing,
China). All care and procedures of all animal experiments were
in accordance with the national guideline for the care and use of
laboratory animals. Animals were inoculated with 2 × 106 cells
(0.1 ml/mouse) intraperitoneally (i.p.). Day “0” was assigned on
tumor implantation day. On day 1, the animals were randomly
divided into five different groups (n= 8). AG36 was administered
i.p. at doses of 0.75, 1.5, and 3.0 mg/kg/day every 2 days. The
CTX treated group was administered i.p. at dose of 25 mg/kg/day
every 2 days. The control group was injected with the same
volume of PBS instead. The tumor volumes were calculated using
the following formula: tumor volume (mm3) = 0.56 × length
(mm) × width2 (square mm). Body weights were recorded every
2 days to value the toxicity of AG36. Mice were sacrificed on
the 17th day and the isolated tumors, livers, spleens, and kidneys
were weighed.
Statistical Analysis
All data were expressed as mean ± SD from three independent
experiments. Data were analyzed statistically by ANOVA.
Statistical comparisons were evaluated using Student’s t-test.
Differences were considered to be significant at P-values less
than 0.05.
RESULTS
AG36 Inhibits Cell Viability and
Proliferation in Breast Cancer Cells
To screen the potential cytotoxic effect of AG36 against breast
cancer, we examined the effect of AG36 on cell proliferation
in MCF-7, MDA-MB-231, and SK-BR-3 cancer cells by MTT
assay. As shown in Figure 2A, AG36 inhibited the viability of
MCF-7, MDA-MB-231, and SK-BR-3 cells in a dose and time-
dependent manner, with IC50 values of approximately 0.73, 18.1,
and 23.4 µM at 48 h, respectively.
Based on the IC50 values, the AG36 concentrations of 0.5, 1.0,
and 1.5 µM for MCF-7 and 10, 15, and 20 µM for MDA-MB-
231 and SK-BR-3 were used in the following study. In order to
determine whether decreased proliferation and cell viability were
associated with apoptosis, the apoptotic effects of AG36 on MCF-
7 cells were investigated using annexin-V/PI double staining by
flow cytometry. As shown in Figure 2B, after 48 h treatment
with AG36, the percentages of apoptotic cells of MCF-7 cells
were from 7.8 to 46.3%. In MCF-7, AG36 noticeably reduced the
surviving cells and increased the early and late apoptotic cells in
a dose-dependent manner.
AG36 Induces Cell Cycle Arrest
Cell cycle arrest is a common mechanism for the cytotoxic
effects of anticancer drug. To investigate the effect of AG36 on
cell cycle arrest, DNA contents in different phases of MCF-7,
MDA-MB-231, and SK-BR-3 cell cycle were performed by flow
cytometry. Treatment with AG36 for 48 h, the number of cells
was remarkably increased in G2/M phase with a concomitantly
decrease in G1 phase compared to control (Figure 3A), indicating
that AG36 could significantly inhibit DNA synthesis of MCF-7,
MDA-MB-231, and SK-BR-3 cells. To understand the possible
molecular events associated with AG36-induced cell cycle arrest
in breast cancer cells, cell cycle regulatory proteins cyclin B1 and
cyclin D1 were examined using Western blot analysis. Exposure
to AG36 for 48 h strongly decreased the expression level of
cyclin B1 and cyclin D1 in MCF-7 cells (Figure 3B). In MDA-
MB-231 and SK-BR-3 cells, AG36 decreased the expression
level of cyclin B1 significantly. These results indicate that AG36
can reduce breast cancer cell proliferation by G2/M-phase cell
cycle arresting through the downregulation of cyclin B1 or
cyclin D1.
Effect of AG36 on Expressions of
Cytochrome c and Bcl-2 Family Proteins
The apoptotic-related proteins Bax and Bcl-2 play a crucial role
in cell apoptosis (Arnoult et al., 2002). The cytochrome c release
from the mitochondria is a necessary requirement to initiate
apoptotic cell death pathway (Kakkar and Singh, 2007). The
effects of AG36 on protein expressions of cytochrome c, Bax
and Bcl-2 in MCF-7, MDA-MB-231, and SK-BR-3 cells were
tested by Western blot analysis. AG36 can induce cytochrome
c release from the mitochondria into the cytoplasm in the three
breast cancer cell lines (Figures 4A,B). In MCF-7 and MDA-MB-
231, AG36 increased the expression of Bax in a concentration-
dependent manner, whereas Bcl-2 expression did not change
apparently as compared with the control group. In SK-BR-3
cells, AG36 decreased the expression of Bcl-2 (Figure 4A). For
all the three breast cancer cells, AG36 treatment increased the
Bax/Bcl-2 ratio (Figure 4B), suggesting that Bcl-2 family proteins
involved in AG36-induced apoptosis in breast cancer cells. These
findings suggest that AG36 could induce apoptosis of MCF-7,
MDA-MB-231, and SK-BR-3 cells by mitochondria-dependent
pathway.
Effects of AG36 on Caspase-3, -8, and -9
Activation
Caspases has been demonstrated to play a central role during
cellular apoptosis (Sun et al., 1999; Wang et al., 2005). Caspase-
3 is a prevalent caspase that is ultimately responsible for the
majority of apoptotic processes and can be activated by upstream
initiator caspases, such as caspase-8 or -9 through two distinct
pathways, i.e., the death receptor-mediated extrinsic caspase-8
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FIGURE 2 | (A) Antiproliferation activity of AG36 on breast cancer cells at different time estimated with the MTT assay. Data were presented as mean ± SD of three
independent experiments. ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001 compared to the control group (B). Flow cytometry detection of apoptosis with annexin V/PI in
MCF-7 cells treated by AG36.
pathway or the mitochondria dependent-cytochrome c/caspase-
9 intrinsic pathway, respectively (Budihardjo et al., 1999; Igney
and Krammer, 2002; Hu and Kavanagh, 2003).
Therefore, we examined the effects of AG36 on the activation
of caspase-3, -8, and -9. As shown in Figure 5A, AG36
increased the protein expression of cleaved caspase-3 and -
8 in a dose-dependent manner in MCF-7 and MDA-MB-231
cells, whereas cleaved caspase-9 did not strongly increase in
response to AG36 treatment, confirming the involvement of
death receptor-mediated pathway in the AG36-induced apoptosis
in MCF-7 and MDA-MB-231 cells. But in SK-BR-3 cells, AG36
dose-dependently increased the protein expression of cleaved
caspase-3 without increasing the cleaved caspase-8 and -9 protein
expressions. These results indicated that caspase-8 or -3 play
pivotal roles in AG36-induced apoptosis of MCF-7, MDA-MB-
231, and SK-BR-3 cells.
To further evaluate the role of caspases in the AG36-induced
apoptosis pathway, we examined whether specific caspase-8
inhibitors, namely z-IETD-fmk block AG36-induced cellular
apoptosis in MCF-7 cells. As shown in Figure 5B, z-IETD-fmk
effectively inhibited AG36-induced MCF-7 cell apoptosis. These
results indicated that AG36-induced apoptosis of MCF-7 cells
was also dependent on the caspase-3 and -8 cascade activation.
Effect of AG36 on Expressions of FasL,
Fas, DR5, and TNFR1 Proteins
In order to test the effect of AG36 on death receptor signal
pathway, we evaluated the contribution of FasL, Fas, DR5, and
TNFR1 to apoptosis of MCF-7, MDA-MB-231, and SK-BR-3 cells
by Western Blot (Figure 6A). When MCF-7 cells were treated
with AG36 for 48 h, FasL, Fas, and TNFR1 were activated in
a dose-dependent manner (Figure 6B), respectively, while DR5
levels did not change apparently, which suggested the activation
of FasL/Fas and TNFR1-signaling apoptotic pathway as well as
the downstream caspase cascade reaction. In MDA-MB 231 cells,
as the dose of AG36 increased, levels of FasL/Fas and DR5 were
upregulated, whereas levels of TNFR1 were almost unchanged.
In SK-BR-3 cells, AG36 only increased the protein expressions of
Fas and FasL without significantly affecting the levels of DR5 and
TNFR1.
Efficacy of AG36 to Inhibit Tumor Growth
in Nude Mice
After revealing the antitumor potential of AG36 in breast
cancer cells in vitro, the antitumor effects of AG36 were also
observed in vivo. MCF-7 cells were subcutaneously inoculated
into the right anterior armpit of nude mice for 7 days, the
mice were assigned to five groups randomly: control treated
group with PBS, AG36 treated group (0.75, 1.5, and 3.0 mg/kg
body weight, i.p. every 2 days), and CTX (cyclophosphamide)
treated group (25 mg/kg body weight, i.p. every 2 days). On the
last day of AG36 treatment (day 17 post-tumor injection), the
tumor volumes significantly reduced compared with the control
group (Figures 7A,B). Compared with control, AG36 at the
concentrations of 1.5 and 3.0 mg/kg significantly decreased the
mean tumor weight (p < 0.05 and p < 0.01) (Figure 7C). AG36
showed no detectable toxicity in all the groups since there were
no statistically significant effects on body weight (Figure 7D),
behavior, and appearance between the AG36 treated groups and
control group. In Table 1, compared with control group, kidney
index of the treated groups showed no significant difference, but
spleen and liver index is significantly higher, which means that
AG36 may improve the body immunity, while have some toxicity
on liver.
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FIGURE 3 | AG36 induced cell cycle arrest in human breast cancer cells. (A) Cells were treated with indicated concentrations of AG36 for 48 h and then were
analyzed by flow cytometry. (B) Western blotting to examine the expression of cyclin B1 and cyclin D1 in MCF-7, MDA-MB-231, and SK-BR-3 cells treated with
AG36 for 48 h. β-Actin expression was used as a loading control. All data are represented as means ± SD of three independent experiments ∗P < 0.05, ∗∗P < 0.01,
and ∗∗∗P < 0.01.
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FIGURE 4 | Effect of AG36 on Bax, Bcl-2, and Cyto.c protein expression of breast cancer cells. (A) Cells were treated with various concentrations of AG36
for 48 h. (B) The Bax/Bcl-2 ratio and cycto.C data were presented as mean ± SD of three independent experiments. ∗P < 0.05, ∗∗P < 0.01 compared to the
control group.
FIGURE 5 | (A) Effects of AG36 on the expression and activation of caspase-3, 8, and 9 in different breast cancer cells. (B) Effects of caspase-8 inhibitors on AG36
induced cell death in MCF-7 cells. Data were presented as mean ± SD of three independent experiments. ∗P < 0.05, ∗∗P < 0.01 compared to the control group.
#P < 0.01 compared to the AG36 group.
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FIGURE 6 | Activation of FasL, Fas, DR5, and TNFR1 in AG36-treated breast cancer cells. (A) Cells were treated with indicated concentrations of AG36 for
48 h. (B) Representative histograms for FasL, Fas, DR5, and TNFR1 expression in breast cancer cells. Data were presented as mean ± SD of three independent
experiments. ∗P < 0.05, ∗∗P < 0.01 compared to the control group.
FIGURE 7 | AG36 inhibits MCF-7 xenograft growth in nude mice. (A) Forty female BALB/c nude mice received an injection of MCF-7 cells and were divided
into four groups. AG36 and CTX were administered at a dose of 0.75, 1.5, 3.0, and 25 mg/kg every other day for a total of six injections. On day 17, mice were
sacrificed and tumor xenografts were excised completely from tissues. Statistical analyses demonstrated the tumor volume (B), tumor weight (C), and body weight
(D) of AG36 treated and control group. ∗p < 0.05 and ∗∗p < 0.01 vs. DMSO group (n = 8).
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TABLE 1 | Effects of AG36 treatment on the liver, kidney, and spleen index
of tumor-bearing mice.
Group Dose
(mg/kg)
Liver
index
Kidney
index
Spleen
index
Control – 42.4 ± 3.2 12.5 ± 3.2 4.6 ± 0.7
CTX 25.0 48.6± 2.7∗∗ 13.7 ± 4.5 4.2 ± 0.4
AG36 (0.75 mg/kg) 0.75 48.5± 8.7∗∗ 13.3 ± 4.2 6.0 ± 0.9∗∗
AG36 (1.5 mg/kg) 1.50 50.4± 3.9∗∗∗ 13.1 ± 4.1 6.1 ± 1.1∗∗
AG36 (3.0 mg/kg) 3.00 52.6± 4.3∗∗∗ 13.4 ± 4.4 6.7± 0.9∗∗∗
∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001 compared with control group.
DISCUSSION
Most breast cancers are diagnosed as ductal invasive carcinomas.
The expression of estrogen receptor (ER), progesterone receptor
(PR), and human epidermal growth factor receptor 2 (HER2)
play crucial roles in ductal-derived breast cancer classification,
diagnose, and treatment (Sorlie et al., 2001). In this study, we
tested the antitumor activity of AG36 against three different
subtype breast tumor cells namely MCF-7 (ER positive, HER2
negative), SK-BR-3 (ER negative, HER2 positive), and MDA-MB-
231 (ER, PR, and HER2 negative).
Apoptosis is a genetically controlled cell-death process and
plays a central role in cancer successful therapy (Bunz, 2001). It
is reported that a wide variety of natural substances have been
recognized to have the ability to induce apoptosis in various
tumor cells of human origin (Taraphdar et al., 2001), which is
regarded as a preferred way of cancer management (Hengartner,
2000; Hsu et al., 2004). In this study, AG36 could decrease the
cell viability of MCF-7, MDA-MB-231, and SK-BR-3 cells in a
dose- and time-dependent manner. AG36 showed more cytotoxic
activity against MCF-7 cells than MDA-MB-231 cells and SK-BR-
3 cells indicating that AG36 may have selective cytotoxic against
ER positive breast cancer cells, which need to be further testified.
At high doses, AG36 increased the proportions of G2/M cells
in MCF-7, MDA-MB-231, and SK-BR-3 cells, the proportions
of G1 cells were decreased accordingly. Cell cycle arresting at
G2/M checkpoint can trigger apoptosis of cancer cells (Pu et al.,
2002; Chao et al., 2004). The phosphorylation of Cdc2/cyclin
B kinase can regulate the transition between the G2 phase and
mitosis (Yarden et al., 2002), which then leads to cell arrest
at the G2/M boundary without progressing to mitosis. If the
DNA damage checkpoint can not be activated, the chromosomes
will irreversibly rearrange and lose genomic integrity. Further
investigations on the effect of AG36 on G1 and G2 cell cycle
regulating proteins cyclin D1 and B1 is warranted (Fang et al.,
2012). Cyclin D1 is a critical regulator essential for G1 phase
progression and has a causative role in breast cancer formation
(Baldin et al., 1993; Yu et al., 2001). Our study indicated that the
treatment of AG36 decreased the expressions of cyclin B1, cyclin
D1 in MCF-7 cells and decreased the expressions of cyclin B1 in
MDA-MB-231 cells and SK-BR-3 cells, respectively. These results
suggested that AG36 could block breast cancer cells proliferation
via modulating cell cycle associated proteins and arresting cells in
the G2/M phase.
We found the Bax/Bcl-2 ratio increased in AG36-treated
MCF-7, MDA-MB-231, and SK-BR-3 cells. It is well known
that the increasing of Bax/Bcl-2 ratio will cause the loss of
mitochondrial membrane potential and release of cytochrome c,
subsequently activate caspase-9, thus ultimately activate the
common downstream apoptosis effector caspase-3. In our study,
AG36 increased the expression of cleaved-caspase-3 and -8 but
did not significantly increase the caspase-9 expression in MCF-
7, MDA-MB-231 cells. In SK-BR-3 cells, AG36 increased the
protein expression of cleaved caspase-3, -8 and -9, but only
cleaved caspase-3 was increased significantly. Which means
AG36 activated the mitochondria dependent intrinsic caspase-
9 pathway together with death receptor-mediated extrinsic
caspase-8 pathway and finally activated the ultimate cleaved
caspase-3. Caspase-8 inhibitor z-IETD-fmk could effectively
inhibit AG36-induced MCF-7 cell death. These results suggested
that except for the mitochondria dependent cytochrome c
intrinsic pathway, the death receptor-mediated extrinsic caspase-
8 pathway may play a more essential role in AG36 induced
apoptosis in MCF-7 cells.
The extrinsic apoptotic pathway involves a super family of
death receptor ligands such as tumor necrosis factor alpha
(TNF-α), TNF-related apoptosis inducing ligand (TRAIL) and
FAS (Ashkenazi and Dixit, 1998). In breast cancer cells, TNF-α
plays a key role in inflammation and cell apoptosis (Baud and
Karin, 2001; Mathiasen et al., 2001; Jin and EI-diery, 2005). TNF-
α exerts its biological functionality by binding two membrane
receptors, tumor necrosis factor receptor 1 (TNFR1) and tumor
necrosis factor receptor 2 (TNFR2) (Mathiasen et al., 2001).
The majority of TNF signaling pathways are attributable to
TNFR1, which can bind both membrane bound and soluble
TNF whereas TNFR2 can only be activated by membrane bound
TNF (Mathiasen et al., 2001). It is also well known that the
FasL/Fas-signaling mediated death receptor apoptotic pathway
is a potential target of antitumor therapy (Ziegler and Kung,
2008). In our study, it showed that the Fas, FasL, and TNFR1
levels in MCF-7 cells increased significantly with the increase of
AG36 concentration. DR4 and DR5 are TRAIL receptors, their
functional activity requires their physical association with lipid
rafts, which serve as plasma membrane platforms for DR initiated
signals in the formation of efficient DISCs (Scheel-Toellner et al.,
2002; Mérino et al., 2007; Lim et al., 2011). The redistribution
of DRs within the plasma membrane in lipid rafts plays an
important role in TRAIL-induced apoptosis (Scheel-Toellner
et al., 2004; Psahoulia et al., 2007). Yan et al. reported that TRAIL
failed to induce the redistribution of DR4 or DR5 in lipid rafts and
may thus explain the reason why breast cancer cells are resistant
to TRAIL (Vanoosten et al., 2005). In the present study, with the
increase of AG36 concentration, DR5 levels in MCF-7 cells didn’t
change significantly. In MDA-MB 231 cells, AG36 increased the
levels of FasL/Fas and DR5 significantly, whereas levels of TNFR1
were almost unchanged. In SK-BR-3 cells, AG36 increased Fas
and FasL protein expressions but didn’t significantly affect the
levels of DR5 and TNFR1. These results suggested that different
breast cancer cells activated the death receptor-mediated extrinsic
caspase-8 pathway through different receptors. To further dissect
the antitumor mechanism of AG36, the in vivo experiments were
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carried out in xenograft animal model. After treated with AG36,
the growth of MCF-7 breast xenografted tumors in the nude
mice was significantly inhibited with no significant body weight
loss. As the results described above, AG36 treatment (1.5 and
3.0 mg/kg/day) and positive control CTX (25 mg/kg) for 17 days
exhibited apparent anti-tumor effect with some toxicity on liver
when compared with control group.
CONCLUSION
In summary, the findings presented in this report demonstrate
that AG36 can inhibit cell survival and proliferation of MCF-
7, MDA-MB-231, and SK-BR-3 cells. The anti-cancer effect was
mainly mediated by cell cycle arresting, increasing ratio of Bax
to Bcl-2 and cytochrome c releasing. The study also revealed that
AG36 mediated anti-cancer effect of different breast cancer cells
via different death receptors-mediated apoptosis and caspases
in a carefully controlled cascade. The in vivo studies showed
that AG36 significantly inhibited the growth of MCF-7 xenograft
tumors in BALB/c nude mice comparing with control. These
obtained findings may provide further insights for AG36 as a
potential human breast cancer therapy.
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